{"id":22,"date":"2017-02-19T21:16:22","date_gmt":"2017-02-19T20:16:22","guid":{"rendered":"https:\/\/site.uit.no\/antbiotic\/?page_id=22"},"modified":"2022-09-05T18:32:31","modified_gmt":"2022-09-05T16:32:31","slug":"news","status":"publish","type":"page","link":"https:\/\/site.uit.no\/antbiotic\/news\/","title":{"rendered":"News & meetings"},"content":{"rendered":"

Consortium Meeting, June 2017<\/strong><\/p>\n

The project team met in Rome, Italy,\u00a0for a\u00a0first joint progress review meeting.<\/p>\n

Start of enrolment –\u00a0first project clinical study<\/strong><\/p>\n

The First Pacient First Visit (FPFV) milestone was achieved on 9th November 2017. This 2-week EBA study aims to identify a suitable combination of \u03b2-lactam antibiotics to treat Tuberculosis.<\/p>\n

Consortium Meeting, February 2018<\/strong><\/p>\n

The project team met in Tromso, Norway, for a two-days project meeting. We discussed progress, milestones achieved, implementation difficulties and\u00a0alternatives moving forward.<\/p>\n

End of the first Reporting Period<\/strong><\/p>\n

We reported progress, activities and costs to the EU after the first 18 project months.<\/p>\n

Consortium Meeting, February 2019<\/strong><\/p>\n

The project team met in Cape Town, South Africa for a progress review meeting. We also visited the project clinical sites and a hospital in the area.<\/p>\n

Start of enrolment –\u00a0second project clinical study<\/strong><\/p>\n

The First Pacient First Visit (FPFV) milestone was achieved on 27th March 2019. This 2-week EBA study aims to\u00a0establish proof of concept of anti-TB efficacy in humans of a low-dose oxaborole drug.<\/p>\n

Consortium Meeting, July 2019<\/strong><\/p>\n

The project team met in Castelldefels, Spain, coinciding with the Tuberculosis Drug Discovery and Development Gordon Research Conference.<\/p>\n

Mid-term review, September 2019
\n<\/strong><\/p>\n

We discussed project progress and plans moving forward with our EU Project Officer.<\/p>\n

Grant Agreement amendment
\n<\/strong><\/p>\n

The global TB pipeline is progressing fast and new knowledge and results are being published. The project team reviewed the work plan and requested a GA amendment to maximize the project impact.<\/p>\n

End of the second Reporting Period<\/strong><\/p>\n

We reported progress, activities and costs to the EU after 36 months of activity.<\/p>\n

Consortium Meeting, May 2020<\/strong><\/p>\n

The project team met by videoconference to discuss project progress and next steps. Our original plan to meet face-to-face in Hamburg was postponed due COVID-19 related mobility restrictions, which are also affecting several project activities.<\/p>\n

Consortium Meeting, October 2020<\/strong><\/p>\n

The project team met by videoconference due to COVID-19 related mobility restrictions. The consortium reviewed progress and timelines, including the possibility of requesting a no-cost extension to complete the planned deliverables. The final decision will be made in 2021.<\/p>\n

End of enrolment –\u00a0first project clinical study<\/strong><\/p>\n

The Last Pacient Last Visit (LPLV) milestone was achieved on 4th January 2021. This 2-week EBA study aims to identify a suitable combination of \u03b2-lactam antibiotics to treat Tuberculosis. The analysis of data and samples will continue over the following months.<\/p>\n

Extension Request, March 2021<\/strong><\/p>\n

The Consortium has requested an extension of six additional months to the project duration.\u00a0Reason for this is petition is due to the COVID-19 impact on the recruitment in clinical trials and the subsequent delay in the project overall progression towards its remaining deliverables and milestones. The extension will allow to adjust the schedule to the new reality and provide enough additional time to complete the recruitment, and progress towards completion of the project objectives. The project will then change from 60 months duration to 66 months duration, with a new final date on 30\/06\/2022.<\/p>\n

Start of enrolment –\u00a0third project clinical study<\/strong><\/p>\n

The First Pacient First Visit (FPFV) milestone was achieved on 1st April 2021. This\u00a0trial will compare therapy outcomes of patients with a biomarker-guided individualized therapy duration\u00a0vs. standard of care.\u00a0This approach has the potential to significantly\u00a0shorten drug-exposure, also reducing adverse events and costs. The identification of patients at risk of therapy failure with need for intensified therapy may also improve patient outcomes and reduce the number of failure cases.<\/p>\n

Consortium Meeting, June 2021<\/strong><\/p>\n

The project team met by videoconference due COVID-19 related mobility restrictions. The consortium reviewed progress and fine-tuned the planning to complete deliverables and achieve milestones at (or before) the project end date, now extended to June 2022, after approval of the Grant Agreement amendment request.\u00a0Being just two weeks ahead of the end of the third reporting period, the partners also reviewed the reporting requirements.<\/p>\n

End of enrolment \u2013 second project clinical study<\/strong><\/p>\n

The Last Pacient Last Visit (LPLV) milestone was achieved on 14th December 2021 with the completion of the fourth cohort. This 2-week Early Bactericidal Activity Phase IIa study aims to establish proof of concept of anti-TB efficacy in humans of a a first-in class low-dose oxaborole drug. The analysis of data and samples will continue over the following months.<\/p>\n

Consortium Meeting, February 2022<\/strong><\/p>\n

The project team met by videoconference and reviewed the roadmap towards project end. Some Work Packages are almost completed however cumulated delays, mainly due to COVID-19 impact, may prevent other workstreams to be fully concluded by the project end date. The Consortium Agreement will be extended to keep a suitable framework for collaboration beyond the funded period.<\/p>\n

Meeting with new EU Project Officer, February 2022<\/strong><\/p>\n

The management team on behalf of the consortium held a meeting with the new Project Officer, after the project was transferred to the new EU unit HaDEA, to present the team, the project progress and the outlook towards project end.<\/p>\n

Consortium Meeting, July 2022<\/strong><\/p>\n

The partners met by videoconference to review the funded period results and discuss future work. The extension of the Consortium Agreement will enable some remaining activities to be completed after the funded period end within a suitable collaborative framework. Several dissemination activities are also scheduled for the coming months.<\/p>\n

End of the fourth and last Reporting Period<\/strong><\/p>\n

We reported progress, activities and costs to the EU after 66 months of activity. The 6-months extension has allowed two clinical trials (WP1 and WP2) and most of the modelling (WP5) and biomarkers work (WP4) to be completed. Unfortunately, the WP3 study could not continue enrolment as initially planned, also affecting the related WP4 activities. Importantly, over the project duration the consortium has been actively working in setting up pathways for exploitation of results, that are already in place, including the EDCTP-funded click-TB project and the EU-funded UNITE4TB project (IMI programme).<\/p>\n

anTBiotic summary of activities and results at project end
\n<\/strong><\/p>\n

See in \u201cPublications and brochures\u201d section.<\/p>\n","protected":false},"excerpt":{"rendered":"

Consortium Meeting, June 2017 The project team met in Rome, Italy,\u00a0for a\u00a0first joint progress review meeting. Start of enrolment –\u00a0first project clinical study The First Pacient First Visit (FPFV) milestone was achieved on 9th November 2017. This 2-week EBA study …<\/p>\n

News & meetings<\/span> Read More »<\/a><\/p>\n","protected":false},"author":283,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-22","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/site.uit.no\/antbiotic\/wp-json\/wp\/v2\/pages\/22","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/site.uit.no\/antbiotic\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/site.uit.no\/antbiotic\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/site.uit.no\/antbiotic\/wp-json\/wp\/v2\/users\/283"}],"replies":[{"embeddable":true,"href":"https:\/\/site.uit.no\/antbiotic\/wp-json\/wp\/v2\/comments?post=22"}],"version-history":[{"count":15,"href":"https:\/\/site.uit.no\/antbiotic\/wp-json\/wp\/v2\/pages\/22\/revisions"}],"predecessor-version":[{"id":207,"href":"https:\/\/site.uit.no\/antbiotic\/wp-json\/wp\/v2\/pages\/22\/revisions\/207"}],"wp:attachment":[{"href":"https:\/\/site.uit.no\/antbiotic\/wp-json\/wp\/v2\/media?parent=22"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}